Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.
Related
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.
Elise Densborn,
Splendid Spoon
From Customer to Co-CEO [Entire Talk]
Passion for a brand or industry can be an incredible starting point for gaining entrepreneurial experience.
Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.
Dante Disparte,
Circle
Ethical Crypto Innovation [Entire Talk]
To build a better crypto industry, start with ethics.
